Description:
CJC-1295 (No DAC) 5mg & Ipamorelin 5mg — Dual GH Pathway Research Peptide Formulation
CJC-1295 (no DAC) and Ipamorelin are combined in a synergistic peptide formulation developed for laboratory research examining endogenous growth hormone (GH) signaling. This pairing brings together a GHRH analogue and a growth hormone–releasing peptide (GHRP), enabling investigation of dual-pathway modulation of GH secretion frequency and amplitude in non-clinical models.
Research areas of interest include:
- Pituitary GH axis signaling and pulsatile growth hormone release dynamics
- Protein synthesis and anabolic signaling research models
- Lipid metabolism and lipolysis pathway investigations
- Sleep-related endocrine patterns and recovery signaling studies
- Connective tissue and muscle regeneration research frameworks
This formulation is frequently utilized as a comprehensive research tool for studying endocrine regulation, performance-recovery mechanisms, and regenerative signaling pathways within controlled laboratory settings.
Intended Use:
For laboratory research use only. Not for human or veterinary use.

